BBPvsXBIETF Comparison
VS
Virtus LifeSci Biotech Products ETF (BBP) belongs to the Tomorrow's Treatments segment. State Street SPDR S&P Biotech ETF (XBI) is part of the US Health Care segment. BBP's top 1 sector exposures are Healthcare. In contrast, XBI's top sector exposures are Healthcare and Finance. BBP is less expensive with a Total Expense Ratio (TER) of 0.34%, versus 0.35% for XBI. BBP is up 29.77% year-to-date (YTD) with +$50M in YTD flows. XBI performs worse with 28.73% YTD performance, and +$551M in YTD flows. Run a side-by-side ETF comparison of BBP and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
BBP vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/10/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | BBP XBI | +2.31%-0.75% | +22.34%+21.86% | +29.77%+28.73% | +48.76%+67.85% | +95.24%+100.33% | +99.54%+19.90% |
| Flows | BBP XBI | +$5M+$117M | +$20M+$1.11B | +$50M+$551M | +$62M+$1.27B | +$68M-$385M | +$61M+$1.51B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | BBP XBI | +26.03%+29.70% | +25.17%+27.98% | +24.72%+28.28% | +26.61%+32.91% |
| Max drawdown | BBP XBI | -9.34%-10.46% | -9.59%-10.46% | -25.54%-32.94% | -37.61%-53.28% |
| Max drawdown duration | BBP XBI | 39d40d | 48d40d | 292d331d | 586d1622d |
Trading data
BBP | XBI | |
Last sale 9/11/2026 at 1:30 PM | $103.46 | $156.20 |
| Previous close 09/10/2026 | $103.47 | $156.82 |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
BBP | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
BBP | XBI | |
|---|---|---|
| Last price | $103.46 | $156.20 |
| 1D performance | -0.01% | -0.40% |
| AuM | $113.85 M | $10.57 B |
| E/R | 0.34% | 0.35% |
Characteristics
BBP | XBI | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | VIRTUS Investment Partners | State Street Investment Management |
| Benchmark | LifeSci Biotechnology Products Index | S&P Biotechnology Select Industry Index |
| N° of holdings | 66 | 149 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | December 16, 2014 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
BBP
USA
86.5%
Other
13.5%
XBI
USA
95.3%
Other
4.7%
Sectors
BBP
Healthcare
98.2%
Other
1.8%
XBI
Healthcare
99.41%
Other
0.59%
Advertisement
Diversification
BBP
Total weight of top 15 holdings out of 15
26.78%
XBI
Total weight of top 15 holdings out of 15
20.29%
Top 15 holdings
Data as of July 31, 2026
BBP
Crinetics Pharmaceuticals, Inc.
3.24%
Verastem, Inc.
1.98%
Nuvation Bio, Inc.
1.80%
Omeros Corp.
1.73%
Geron Corp.
1.72%
BridgeBio Pharma, Inc.
1.68%
Agios Pharmaceuticals, Inc.
1.67%
Protagonist Therapeutics, Inc.
1.65%
BeOne Medicines Ltd.
1.64%
Kiniksa Pharmaceuticals International Plc
1.63%
Precigen, Inc.
1.62%
Xeris Biopharma Holdings, Inc.
1.61%
ACADIA Pharmaceuticals, Inc.
1.60%
Iovance Biotherapeutics, Inc.
1.60%
Rhythm Pharmaceuticals, Inc.
1.60%
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
Frequently asked questions about BBP and XBI
How have the BBP and XBI ETFs performed in 2026?
As of September 10, 2026, BBP is up 29.77% year-to-date (YTD), while XBI has returned 28.73%. That puts BBP better performer ahead so far this year.
Which ETF is attracting more investor money: BBP or XBI?
Year-to-date, the BBP ETF saw +$50M in flows, compared to +$551M for XBI.
Which ETF is more volatile: BBP or XBI?
Over the past year, BBP had a volatility of 25.17%, while XBI experienced 27.98%.
Which ETF is bigger: BBP or XBI?
As of September 10, 2026, BBP holds $113.85 M in assets under management (AUM), while XBI manages $10.57 B.
What sectors do the BBP and XBI ETFs invest in?
BBP leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the BBP ETF and XBI ETF?
BBP top holdings include Crinetics Pharmaceuticals, Inc., Verastem, Inc. and Nuvation Bio, Inc.. XBI holds in its top three: Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc..
Which ETF is more diversified: BBP or XBI?
BBP holds 66 securities with 26.78% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 20.29%.
Advertisement
Latest news about BBP & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
